Bugworks Research, a clinical-stage biopharmaceutical company, and Cytecare Cancer Hospitals announced on Monday the launch of a dedicated immuno-oncology research center within the cancer hospital.
The ex vivo research laboratory dedicated to immuno-oncology aims to bridge the gap between discovery and development, treating several difficult-to-treat cancers such as gastric, colorectal, renal cell, breast, head cancers and neck and non-small cell lung. cancers.
“We are discovering novel, highly differentiated small-molecule immunotherapeutic agents that target the immunosuppressive and tumor-promoting microenvironment. Cytecare Cancer Hospitals ex vivo labs, as part of our collaboration, will go a long way in translating our research into a high percentage of successful clinical outcomes,” said V. Balasubramanian, co-founder and COO of Bugworks.
Bugworks’ current research in immuno-oncology is focused on modulating the tumor microenvironment that includes adenosine antagonism, an area of research with applications in many solid tumors. The drug candidates resulting from this research will undergo translational testing in patient-derived tumors in Cytecare’s ex vivo laboratories, before moving on to first-in-man clinical studies.
Suresh Ramu, Co-Founder and CEO of Cytecare Cancer Hospitals, said, “We are delighted to partner with Bugworks Research, in this inspiring endeavor to discover new treatments for different types of cancers. At Cytecare, we are committed to providing the best possible treatment to patients and supporting advanced research. We believe that affordable and accessible immuno-oncology therapies can come from India and be made accessible to all patients. This collaboration heralds a brave new start towards a healthier future.
September 19, 2022